Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

posttransplant acute limbic encephalitis (PALE) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

posttransplant acute limbic encephalitis

MONDO:0015595

Also known as:PALE

Overview

Posttransplant acute limbic encephalitis is a rare, acquired, non-paraneoplastic limbic encephalitis disorder, that develops in the setting of treatment-related immunosuppression, typically after allogeneic hemapoietic stem cell transplantation, characterized by onset of confusion, headache, anterograde amnesia, seizures and/or loss of consciousness 2-6 weeks following transplantation. Bilateral, non-enhancing T2 hyperintensities in limbic structures are observed on magnetic resonance imaging. Mild cerebrospinal fluid pleocytosis and syndrome of inappropriate antidiuretic hormone secretion may also be associated.

ResearchLimited published research (4 articles)

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for posttransplant acute limbic encephalitis.

4 publications have been identified in PubMed for posttransplant acute limbic encephalitis. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (25%), and Epidemiology / Natural History (25%).

Recent Publications

Yoshimura T (2026). [PMID: 41734634](https://pubmed.ncbi.nlm.nih.gov/41734634/). *Brain & development*. [Case Report / Case Series]
Thomas DT (2025). [PMID: 40329455](https://pubmed.ncbi.nlm.nih.gov/40329455/). *Annals of Indian Academy of Neurology*. [Epidemiology / Natural History]
Goto Y (2025). [PMID: 40546590](https://pubmed.ncbi.nlm.nih.gov/40546590/). *Cureus*. [Case Report / Case Series]
Kampouri E (2024). [PMID: 38726832](https://pubmed.ncbi.nlm.nih.gov/38726832/). *Current opinion in infectious diseases*. [Review / Meta-Analysis]

Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:54 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:163921

GARD

Genetic and Rare Diseases Info Center

GARD:20051

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

posttransplant acute limbic encephalitis

Overview

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team